13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q1 2024 · Filed May 3, 2024 · Accession 0000950123-24-003797
Total Value
$103.1M
Positions
7
Other Managers
0
Confidential Omitted
No
Holdings (7)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CRISPR Therapeutics AG | CRSP | 498,558 | $34.0M | 32.95% |
| 2 | Skye Bioscience, Inc. | SKYE | 2,007,702 | $31.4M | 30.45% |
| 3 | Repare Therapeutics, Inc. | 760273102 | 2,646,657 | $12.5M | 12.09% |
| 4 | Gritstone Oncology, Inc. | 39868T105 | 3,561,150 | $9.2M | 8.87% |
| 5 | Adverum Biotechnologies, Inc. | 00773U108 | 506,822 | $7.2M | 6.95% |
| 6 | Passage Bio, Inc. | PASG | 4,959,769 | $6.7M | 6.49% |
| 7 | Aligos Therapeutics, Inc. | ALGS | 2,320,381 | $2.3M | 2.20% |